Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Mischoulon, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by David Mischoulon and Cristina Cusin.
Connection Strength

3.343
  1. All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment. Am J Psychiatry. 2020 02 01; 177(2):173-174.
    View in: PubMed
    Score: 0.880
  2. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. J Affect Disord. 2020 11 01; 276:660-666.
    View in: PubMed
    Score: 0.227
  3. Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder. J Affect Disord. 2020 02 01; 262:118-125.
    View in: PubMed
    Score: 0.216
  4. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 11 01; 258:102-108.
    View in: PubMed
    Score: 0.211
  5. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. J Affect Disord. 2019 01 15; 243:516-524.
    View in: PubMed
    Score: 0.200
  6. Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]. J Affect Disord. 2018 02; 227:198.
    View in: PubMed
    Score: 0.188
  7. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry. 2017 Jan; 51(1):55-64.
    View in: PubMed
    Score: 0.178
  8. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017 Jan 15; 208:6-14.
    View in: PubMed
    Score: 0.175
  9. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. J Clin Psychiatry. 2016 06; 77(6):e719-25.
    View in: PubMed
    Score: 0.171
  10. Treatment Outcome in Depressed Latinos Predicted by Concomitant Psychosislike Symptoms. J Nerv Ment Dis. 2015 Oct; 203(10):769-73.
    View in: PubMed
    Score: 0.163
  11. Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study. J Psychiatr Res. 2015 Nov; 70:98-105.
    View in: PubMed
    Score: 0.162
  12. Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. Asian J Psychiatr. 2015 Feb; 13:23-9.
    View in: PubMed
    Score: 0.154
  13. Monitoring Changes in Depression Severity Using Wearable and Mobile Sensors. Front Psychiatry. 2020; 11:584711.
    View in: PubMed
    Score: 0.058
  14. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020 10 01; 177(10):965-973.
    View in: PubMed
    Score: 0.057
  15. Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study. J Clin Psychiatry. 2020 06 09; 81(4).
    View in: PubMed
    Score: 0.056
  16. Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. Psychol Med. 2020 Mar 06; 1-9.
    View in: PubMed
    Score: 0.055
  17. The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause. Psychoneuroendocrinology. 2020 02; 112:104512.
    View in: PubMed
    Score: 0.054
  18. Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. Photomed Laser Surg. 2018 Dec; 36(12):634-646.
    View in: PubMed
    Score: 0.050
  19. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84.
    View in: PubMed
    Score: 0.047
  20. Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. Psychiatry J. 2015; 2015:352979.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.